https://orcid.org/0000-0002-4692-7499
References
- Branstrom A, Cao L, Furia B, Trotta C, Santaguida M, Graci JD, Colacino JM, Ray B, Li W, Sheedy J, et al. 2022. Emvododstat, a potent dihydroorotate dehydrogenase inhibitor, is effective in preclinical models of acute myeloid leukemia. Front Oncol. 12:832816.
- Cao L, Weetall M, Bombard J, Qi H, Arasu T, Lennox W, Hedrick J, Sheedy J, Risher N, Brooks PC, et al. 2016. Discovery of novel small molecule inhibitors of VEGF expression in tumour cells using a cell-based high throughput screening platform. PLoS One. 11(12):e0168366.
- Cao L, Weetall M, Trotta C, Cintron K, Ma J, Kim MJ, Furia B, Romfo C, Graci JD, Li W, et al. 2019. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favourable pharmaceutical properties. Mol Cancer Ther. 18(1):3–16.
- Gao H, Jacobs A, White RE, Booth BP, Obach RS. 2013. Meeting report: metabolites in safety testing (MIST) symposium – safety assessment of human metabolites: What’s REALLY necessary to ascertain exposure coverage in safety tests? Aaps J. 15(4):970–973.
- Holm R, Müllertz A, Mu H. 2013. Bile salts and their importance for drug absorption. Int J Pharm. 453(1):44–55.
- Ignacio RAB, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE. 2016. A phase 1b/pharmacokinetic trial of PTC299, a novel post transcriptional VEGF inhibitor, for AIDS-related Kaposi’s sarcoma: AIDS Malignancy Consortium trial 059. J Acquir Immune Defic Syndr. 72 (1):52–57.
- Kester JE. 2014. Liver. In: Wexler P, editor. Encyclopedia of toxicology. 3rd ed. London (UK): Academic Press; p. 96–106.
- Luban J, Sattler R, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-DeCastillia C, et al. 2021. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Res. 292:198246.
- Ma J, Kaushik D, Yeh S, Northcutt V, Babiak J, Risher N, Weetall M, Moon YC, Welch EM, Molony L, et al. 2022. In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor. Xenobiotica. 52(2):152–164.
- Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, et al. 2015. Phase 1 and pharmacokinetic trial of PTC299 in paediatric patients with refractory or recurrent central nervous system tumours: a PBTC study. J Neurooncol. 121(1):217–224.
- U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research. 2020. Guidance for Industry: safety Testing of Drug Metabolites. March 2020.
- Weetall M, Davis T, Elfring G, Northcutt V, Cao L, Moon YC, Riebling P, Dali M, Hirawat S, Babiak J, et al. 2016. Phase 1 study of safety tolerability and pharmacokinetics of PTC299, an inhibitor of stress-regulated protein translation. Clin Pharmacol Drug Dev. 5(4):296–305.